San Francisco, March 21, 2019 – Recardio announced today that it presented at the Cell & Gene Therapy Conference in New York.
This one-day meeting is the only U.S.-based conference showcasing clinical and commercial thought leaders as well as 30+ investor-validated companies exclusively in the cell and gene therapy space. Nearly 400 institutional, venture and corporate investors as well as senior executives are joining to evaluate upcoming clinical and commercial milestones as well as key investment opportunities in the sector.
The Cell & Gene Therapy Conference was held on March 21, 2019 in New York.
Recardio presented its latest advancements from its drug-based regenerative therapy clinical development program and gave a future outlook on new therapies and expansion programs.
More information about the clinical program is available by visiting the following link.
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/